Kanghong Pharmaceuticals: Clinical trial of zuminaplun slow release capsule hydrochloric acid has been approved by NMPA

Today, Chengdu Kanghong Pharmaceuticals announced that the company recently received the State Drug Administration issued on the hydrochloric acid Zuminaplun slow release capsule "drug clinical trial approval notice" (notice number: 2020LP000577, 2020LP00578, 2020LP000579).
In accordance with the Drug Administration Law of the People's Republic of China and the relevant provisions, after examination, the company declared that the hydrochloric acid Zuminaplun slow release capsule meets the relevant requirements of drug registration, agreed to carry out human biological equivalent testing and validation clinical trials for depression.
Approval Notice Basic Information Drug Name: Hydrochloric Acid Zuminaplun Slow Release Capsule Dosage Form: Slow Release Capsule Specification: 20mg, 40mg, 80mg Adaptation: Depression Review Conclusion: Agree to conduct human bioethics trials and laboratory clinical trials for depression.
hydrochloric acid zominaplun slow release capsule is a 5 serotonin and dethynephrine re-extraction inhibitor, suitable for the treatment of depression.
the drug according to the registration classification of the new 3 categories approved to carry out clinical trials, at present, no other domestic enterprises have been approved for listing.